Key Highlights
- FDA has accepted priority review for two supplemental Biologics License Applications covering KEYTRUDA and KEYTRUDA QLEX, both administered alongside Padcev.
- The regulatory submissions focus on muscle-invasive bladder cancer (MIBC) patients who qualify for cisplatin-based chemotherapy treatment.
- Regulators established an August 17, 2026 target action date under the Prescription Drug User Fee Act.
- Supporting evidence comes from the Phase 3 KEYNOTE-B15 clinical trial, demonstrating enhanced survival results.
- Approval would mark the first perioperative therapy option for MIBC patients irrespective of cisplatin treatment eligibility.
Merck has secured another promising regulatory pathway for KEYTRUDA, its flagship oncology treatment, after receiving priority review designation for two bladder cancer applications from federal regulators.
The pharmaceutical company disclosed Monday that federal regulators accepted two supplemental Biologics License Applications covering KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph). Each application proposes combining the therapy with Padcev (enfortumab vedotin-ejfv) for treating muscle-invasive bladder cancer patients eligible for cisplatin-containing chemotherapy regimens.
Regulators scheduled the Prescription Drug User Fee Act target action date for August 17, 2026.
The priority review designation applies to therapies potentially delivering significant therapeutic advances for serious medical conditions. This expedited pathway generally compresses review timelines to approximately six months, versus the conventional ten-month standard.
Clinical Trial Results
Both regulatory submissions draw support from the Phase 3 KEYNOTE-B15 clinical trial. The study demonstrated superior survival benefits among muscle-invasive bladder cancer patients receiving the KEYTRUDA and Padcev combination therapy.
While Merck withheld detailed trial statistics from Monday’s disclosure, the FDA’s priority review decision suggests regulators view the evidence as potentially transformative for clinical practice.
Present regulatory approval permits KEYTRUDA combined with Padcev for adult patients diagnosed with locally advanced or metastatic urothelial cancer across the United States, European Union, Japan, and additional markets.
These pending applications aim to broaden that authorization into earlier disease stages—specifically the muscle-invasive setting—where therapeutic goals typically emphasize cure rather than palliation.
Pioneering Treatment Classification
Regulatory approval would establish the KEYTRUDA and KEYTRUDA QLEX combinations with Padcev as inaugural perioperative therapies for MIBC patients without regard to cisplatin treatment eligibility.
This represents significant clinical differentiation. Current approvals authorize the combination for MIBC patients unsuitable for cisplatin-based chemotherapy. The new regulatory submissions would encompass cisplatin-eligible patients—substantially expanding the addressable patient population.
Perioperative therapy encompasses treatment administered surrounding surgical intervention, which represents standard care for muscle-invasive bladder cancer. Securing this treatment setting through priority review positions Merck advantageously from a regulatory standpoint approaching the August decision deadline.
KEYTRUDA QLEX constitutes a subcutaneous formulation of pembrolizumab, enabling administration through under-skin injection rather than intravenous infusion. This delivery method may provide practical advantages compared to conventional IV administration.
Merck shares advanced 3.13% Monday following the announcement. The August 17 target date now represents a critical milestone for investors monitoring the company’s oncology development portfolio.
